{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-264582","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2021-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.058584+00:00","generated_at":"2026-06-29T06:00:00.141729+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Acadia CFO Elena Ridloff resigns; CEO Davis named principal financial officer","bullets":["Elena Ridloff resigned as EVP and CFO effective September 10, 2021.","CEO Stephen Davis appointed as principal financial officer.","Mark Schneyer appointed interim CFO; remains SVP and Chief Business Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-264582","json":"https://secwatch.observer/filing/0001193125-21-264582.json","markdown":"https://secwatch.observer/filing/0001193125-21-264582.md","text":"https://secwatch.observer/filing/0001193125-21-264582.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000119312521264582/0001193125-21-264582-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000119312521264582/d206699d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T06:00:00.141729+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8caa4c6f93","claim":"Elena Ridloff resigned as Executive Vice President and Chief Financial Officer at ACADIA PHARMACEUTICALS INC.","evidence_excerpt":"Elena Ridloff gave notice on August 30, 2021 of her resignation as Executive Vice President and Chief Financial Officer of Acadia Pharmaceuticals Inc. (the “Company”), effective September 10, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070494/000119312521264582/0001193125-21-264582-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Vice President and Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"b47e0126e0","claim":"Stephen Davis was appointed as principal financial officer at ACADIA PHARMACEUTICALS INC.","evidence_excerpt":"On August 31, 2021, the Board of Directors of the Company (the “Board”) appointed Stephen Davis, the Company’s Chief Executive Officer, as the Company’s principal financial officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070494/000119312521264582/0001193125-21-264582-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal financial officer"}],"fact_type":"executive_change"},{"claim_id":"ee367e3a3c","claim":"Mark Schneyer was appointed as interim Chief Financial Officer at ACADIA PHARMACEUTICALS INC.","evidence_excerpt":"The Board also appointed Mark Schneyer as the Company’s interim Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070494/000119312521264582/0001193125-21-264582-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}